Inclusion Criteria:

          -  Has a histologically confirmed diagnosis of locally advanced/metastatic ccRCC

          -  Has received no prior systemic therapy for advanced RCC; prior neoadjuvant/adjuvant
             therapy for RCC is acceptable if completed ≥12 months before randomization/allocation

          -  Is able to swallow oral medication

          -  Has adequate organ function

          -  Participants receiving bone resorptive therapy must have therapy initiated at least 2
             weeks before randomization/allocation

          -  Has resolution of toxic effects of the most recent prior therapy to ≤Grade 1

          -  If participants receive major surgery or radiation therapy, they must have recovered
             from complications from the intervention

          -  Has adequately controlled blood pressure (BP ≤150/90 mm Hg) with no change in
             hypertensive medications within 1 week before randomization/allocation

          -  Male participants are abstinent from heterosexual intercourse or agree to use
             contraception during treatment with and for at least 7 days after the last dose of
             lenvatinib and /or belzutifan; 7 days after lenvatinib and/or belzutifan is stopped,
             if the participant is only receiving pembrolizumab, pembrolizumab/quavonlimab,
             favezelimab/pembrolizumab or a combination of the aforementioned drugs, no
             contraception is needed

          -  Female participant is not pregnant or breastfeeding and is not a woman of childbearing
             potential (WOCBP) or is a WOCBP abstinent from heterosexual intercourse or using
             contraception during the intervention period and for at least 120 days after the last
             dose of pembrolizumab, pembrolizumab/quavonlimab, favezelimab/pembrolizumab for 30
             days after the last dose of lenvatinib or belzutifan, whichever occurs last

        Exclusion Criteria:

          -  Has urine protein ≥1 g/24 hours and has any of the following: (a) hypoxia defined as a
             pulse oximeter reading <92% at rest, or (b) requires intermittent supplemental oxygen,
             or (c) requires chronic supplemental oxygen

          -  Has clinically significant cardiovascular disease within 12 months from the first dose
             of study intervention administration

          -  Has had major surgery within 3 weeks before first dose of study interventions

          -  Has a history of lung disease

          -  Has a history of inflammatory bowel disease

          -  Has preexisting gastrointestinal (GI) or non-GI fistula

          -  Has malabsorption due to prior GI surgery or disease

          -  Has received prior radiotherapy within 2 weeks of start of study intervention

          -  Has received a live or live attenuated vaccine within 30 days before the first dose of
             study drug; killed vaccines are allowed

          -  Has received more than 4 previous systemic anticancer treatment regimens

          -  Has a diagnosis of immunodeficiency or is receiving any form of immunosuppressive
             therapy within 7 days prior to the first dose of study intervention

          -  Has known additional malignancy that is progressing or has required active treatment
             within the past 3 years

          -  Has known central nervous system (CNS) metastases and/or carcinomatous meningitis

          -  Has an active autoimmune disease that has required systemic treatment in the past 2
             years; replacement therapy is not considered a form of systemic treatment and is
             allowed

          -  Has an active infection requiring systemic therapy

          -  Has a known history of human immunodeficiency virus (HIV) infection

          -  Has a known history of Hepatitis B

          -  Has had an allogenic tissue/solid organ transplant